Patents by Inventor Marc Ferrer-Alegre

Marc Ferrer-Alegre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In vitro tissue plate
    Patent number: 11767498
    Abstract: An in vitro tissue plate may include a well plate, a fluidic plate disposed on a bottom surface of the well plate, and a media manifold disposed on a bottom surface of the fluidic plate. The well plate may have at least two wells, including a tissue well and a waste well. The fluid plate may include a fluid channel extending between and fluidly connecting the tissue well to the waste well. The media manifold may include a one or more media outlets fluidly connected to the fluid channel. A tissue layer may be deposited in the tissue well. The tissue layer may include human cells such as neurovascular cells.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 26, 2023
    Assignees: Massachusetts Institute of Technology, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Johanna Bobrow, Todd Thorsen, David Walsh, Christina Zook, Min Jae Song, Marc Ferrer-Alegre, Sam Michael, Yen-Ting Tung, Molly Elizabeth Boutin
  • METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
    Publication number: 20220389505
    Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
    Type: Application
    Filed: July 15, 2022
    Publication date: December 8, 2022
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Kapil Bharti, Janine Davis, Arvydas Maminishkis, Marc Ferrer-Alegre, Sheldon S. Miller
  • Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders
    Patent number: 10239830
    Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 26, 2019
    Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, The United States of America, as represented by the Secretary, Depart. of Health and Human Services
    Inventors: Samarjit Patnaik, Mercedes Taylor, Raul Rolando Calvo, Juan Jose Marugan, Noel Southall, Wei Zheng, Marc Ferrer-Alegre, Seameen Dehdasthi, Patricia Dranchak, Fannie Chen, Yiannis Ioannou
  • Modulators of the relaxin receptor 1
    Patent number: 10125112
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 13, 2018
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
    Publication number: 20180291448
    Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: October 11, 2018
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Kapil Bharti, Janine Davis, Arvydas Maminishkis, Marc Ferrer-Alegre, Sheldon S. Miller
  • BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS
    Publication number: 20180044286
    Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 15, 2018
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, and Human Services
    Inventors: Samarjit PATNAIK, Mercedes TAYLOR, Raul Rolando CALVO, Juan Jose MARUGAN, Noel SOUTHALL, Wei ZHENG, Marc FERRER-ALEGRE, Seameen DEHDASTHI, Patricia DRANCHAK, Fannie CHEN, Yiannis IOANNOU
  • MODULATORS OF THE RELAXIN RECEPTOR 1
    Publication number: 20170144984
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Application
    Filed: August 25, 2016
    Publication date: May 25, 2017
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • Modulators of the relaxin receptor 1
    Patent number: 9452973
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 27, 2016
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
    Publication number: 20150368713
    Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
    Type: Application
    Filed: January 31, 2014
    Publication date: December 24, 2015
    Applicant: THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Kapil Bharti, Janine Davis, Arvydas Maminishkis, Marc Ferrer-Alegre, Sheldon S. Miller
  • MODULATORS OF THE RELAXIN RECEPTOR 1
    Publication number: 20150119426
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 30, 2015
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik